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Abstract
Background: Thyroid hormones regulate cell proliferation, differentiation as well as apoptosis. However molecular
mechanism underlying apoptosis as a result of thyroid hormone signaling is poorly understood. The antiapoptotic role of
Senescence Marker Protein-30 (SMP30) has been characterized in response to varieties of stimuli as well as in knock out
model. Our earlier data suggest that thyroid hormone 3, 395 Triiodo L Thyronine (T3), represses SMP30 in rat liver.
Methodology/Principal Findings: In highly metastatic MCF-7, human breast cancer cell line T3 treatment repressed SMP30
expression leading to enhanced apoptosis. Analysis by flow cytometry and other techniques revealed that overexpression
and silencing of SMP30 in MCF-7 resulted in decelerated and accelerated apoptosis respectively. In order to identify the cis–
acting elements involved in this regulation, we have analyzed hormone responsiveness of transiently transfected hSMP30
promoter deletion reporter vectors in MCF-7 cells. As opposed to the expected epigenetic outcome, thyroid hormone down
regulated hSMP30 promoter activity despite enhanced recruitment of acetylated H3 on thyroid response elements (TREs).
From the stand point of established epigenetic concept we have categorised these two TREs as negative response
elements. Our attempt of siRNA mediated silencing of TRb, reduced the fold of repression of SMP30 gene expression. In
presence of thyroid hormone, Trichostatin- A (TSA), which is a Histone deacetylase (HDAC) inhibitor further inhibited SMP30
promoter activity. The above findings are in support of categorisation of both the thyroid response element as negative
response elements as usually TSA should have reversed the repressions.
Conclusion: This is the first report of novel mechanistic insights into the remarkable downregulation of SMP30 gene
expression by thyroid hormone which in turn induces apoptosis in MCF-7 human breast cancer cells. We believe that our
study represents a good ground for future effort to develop new therapeutic approaches to challenge the progression of
breast cancer.
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Introduction
The incidence of breast cancer has shown an alarming increase
trend in recent years [1]. An estimated 1.7 million women will be
diagnosed with breast cancer in 2020 which is a 26% increase
from the current levels, mostly in the developing world [2,3]. The
development and growth of many human cancers including breast
cancers are known to be influenced by steroid hormones [4,5].
Abnormal responsiveness of the cells especially to estrogen hor-
mone has been a major cause of breast cancer development and
progression [6,7]. Therefore better understanding and manipu-
lation of the endocrine milieu may provide effective palliative
treatment for patients with hormone-dependent cancers [8,9,10].
Numerous environmental risk factors, pathological conditions
and physiological agents as well as thyroid hormones have been
proposed to influence the development of breast cancer [11].
Interestingly, Martinez et al reported that the addition of thyroid
hormones at non physiological concentrations can alter mammary
epithelial cells proliferation [12].
The thyroid gland releases two potent hormones, triiodothyro-
nine (T3) and thyroxine (T4), which can influence and alter the
basal metabolism or the oxygen consumption in virtually every cell
in the body. However, due to conflicting results regarding the
clinical correlation between breast cancer and thyroid diseases,
any precise association between thyroid status and the pathogen-
esis of human breast cancer remains elusive [13]. Similar pathways
are shared between thyroid hormone and estrogen in regulating
proliferation and growth in the target cells, including cancer cells.
So the aberrant signaling by these hormones needs to be evalu-
ated in terms of regulated growth or cancer of the target cells.
Receptors of these hormones are critically important in the above
process of evaluation. Although the secretion of T4 from thyroid is
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times more effective than the former. T3 binds to specific high
affinity receptors called thyroid receptors (TRs) which belong to
the super family of nuclear receptors [14] and mediate multiple
effects on the phenotype, proliferation and gene expression of cul-
tured normal mammary epithelial cells [15,16,17].
The TRs are ligand modulated transcription factors encoded
by two genes, TRa and TRb, located on human chromosomes 17
and 3 respectively [11]. Dependency of human mammary neo-
plasia on thyroid hormones and controversial reports in literature
about the relationship between the thyroid status of the patient
and neoplastic illness [18,19,20] have suggested that thyroid
hormone receptors (TRs) could potentially become a marker and a
therapeutic target like the estrogen and progesterone receptors
[21]. One of the recent studies reports substantial changes in the
expression profile of TRs in breast cancer cells, suggesting a possi-
ble deregulation of TRs which could trigger breast cancer develop-
ment [21,22,23]. However, only a few reports have described the
presence of TRs in breast tumors [24,25] and breast cancer cell
lines [26,27]. MCF-7 is one of the well defined breast cancer cell
lines where presence of receptors for thyroid hormone has been
well documented [26]. This finding makes it a suitable model to
study the effect of thyroid hormones in breast cancer.
The effect of thyroid hormone at the cellular level is mediated
through TRs, by interacting with thyroid hormone response
elements (TREs) in the promoters of the target genes to regulate
transcription. Depending on their ability to bind to thyroid hor-
mone, TRs can activate or suppress gene expression in a tissue
specific manner through heterodimerisation with retinoid X re-
ceptors (RXRs) and interaction with the positive or negative
response elements commonly known as TREs in the regulatory
regions of target genes [28]. The molecular mechanism of positive
transcriptional regulation by TRs is well established. However, the
molecular mechanism of negative regulation by nuclear receptors
is poorly understood. Several hypotheses have been proposed to
explain the action of TR on negative TREs [29]. One hypothesis
is that the TR directly regulates transcription through direct
binding to target promoter, either to unusual DNA response
elements or via protein-protein interactions with other transcrip-
tion factors associated with cognate response elements. Another
hypothesis suggests that the role of TR is indirect mediated
through the squelching of coregulators from other transcription
factors. Silencing mediator for retinoic and thyroid hormone
receptor (SMRT) and nuclear corepressor (NCoR) can increase
basal transcription of some target genes in absence of ligand [30].
Coactivator also can play an apparently paradoxical role in T3
dependent negative regulation of some target genes [31]. On the
other hand HDACs are recruited by TRs during ligand dependent
negative regulation in other cases [32]. Thus, cofactor associated
changes in histone acetylation, and alterations in chromatin
structure, may be involved in T3 mediated negative regulation. Of
note, not all negatively regulated target genes are activated in
absence of ligand, suggesting that cofactors may be differentially
recruited to promoters of negatively regulated target genes [33].
However there is no consensus over exact mechanism of negative
regulation by TRs so far. The response elements may be defined as
a negative response element if despite having the basic attribute of
an open chromatin conformation such as increased recruitment
of acetylated histone recruitment; the outcome is the repression
of the corresponding gene.
The role of thyroid hormones in inducing apoptosis in different
systems has been well documented in literature [34, 35 and 36].
SMP30 was initially identified as a novel protein that is highly
expressed in hepatocytes and in renal tubular epithelia, and its
amount decreases with aging [37]. The anti-apoptotic role of
SMP30 has been well documented in several reported investiga-
tions [38–41]. Thus thyroid hormones and SMP30 seem to influ-
ence the process of apoptosis in a manner opposite to each other.
Hence, it is worth investigating the effect of thyroid hormones on
expression and functioning of SMP30 gene in breast cancer cells in
which programmed cell death is deregulated. Additionally, we
observed downregulation of SMP30 expression in rat liver by
thyroid hormone [42]. Interestingly; MCF-7 breast cancer cells
express SMP30, which is an antiapoptotic gene.
The mechanism underlying thyroid hormone induced regula-
tion of SMP30 level in breast cancer cells as well as the role of
thyroid hormones against breast cancer cells has not been ad-
dressed. In our current study, we have attempted to explore the
importance of SMP30 gene, molecular mechanism of its regulation
and consequences in response to thyroid hormone treatment in
MCF-7 cells. These highly metastatic breast cancer cells are found
to have endogenous expression of TRs as well as SMP30. Here, we
are providing promising data in support of challenging breast
cancer by targeting thyroid hormone receptors which might
provide enough supplementary strength to interfere breast cancer
metastasis by adjuvant therapies such as Selective estrogen recep-
tor modulators (SERMs).
Results
Downregulation of SMP30 gene in MCF-7 cell line by 3,
395 triiodo L thyronine
MCF-7 breast cancer cells express a substantially good amount
of SMP30 which is a well established antiapoptotic gene. Here we
have examined the effect of thyroid hormone on SMP30 gene
expression both at transcriptional and translational level. Fig.1
shows that overnight treatment of thyroid hormone downregulate
SMP30 protein expression in MCF-7 cells. Although TRs are
present endogenously in MCF-7 cells, we over expressed them
along with RXRa to maintain appropriate amount of function-
ally active TRs in these breast cancer cells. It is known that
thyroid hormone receptors can bind to a TRE as monomers, as
homodimers or as heterodimers with the RXR. Although the
heterodimer affords the highest binding affinity, and is thought to
represent the major functional form of the receptor, it would be
interesting to analyze the effect of T3 on SMP30 expression in
MCF-7 cells not transfected with RXRa. Expression of SMP30
was significantly downregulated in presence of only TRs but
there was no further repression when both TRs and RXRa were
overexpressed as shown in Fig.1B. Overexpression of TRs and
RXRa in MCF-7 cells were confirmed by Western blot analysis
as shown in Fig.1A, B. In addition we also demonstrated that
SMP30 expression was significantly repressed at RNA level by T3
treatment in both TRs and RXRa overexpressed MCF-7 cells
than MCF-7 mock cells by real time PCR as in (Fig. 1C, D).
Identification of high affinity TR binding sites within
SMP30 Promoter
To determine whether there were any TR binding sites within
human SMP30 (hSMP30) promoter, we performed an electropho-
retic mobility shift assay (EMSA). We have scanned for TREs
within 2 kb hSMP30 promoter from transcription start site.
Transcription start site of hSMP30 gene was analysed by primer
extension analysis as shown in Fig. S1. TRs can bind TREs as
monomers, homodimers, or heterodimers with the RXR positively
or negatively regulate gene expression depending on the nature of
TRE and the presence of T3. TREs are generally composed of
two or more TR binding half sites arranged as direct repeats
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spacer, or inverted palindromes spaced by six nucleotides [43].
The optimal TR binding half site is the octamer TAGGTCA, an
extended version of the common core response element hexamer
AGGTCA [44]. In hSMP30 promoter we got two TR binding half
sites i.e. at 613 bp and 1.2 kbp from hSMP30 transcription start
site. The sequence of the former from 2637 to 2600 was found to
be ATGTTGGTCAGGCTGGTCTCAAACTCCTGACCT-
TAGG and that of later from 21274 to 21235 was GAA-
GGACATTAAAGGGACAATTTCTATGACCTGGTG. These
two DNA fragments were
32P-labeled, incubated with nuclear
extract (N.E) of MCF-7 cells - transfected with TRa,T R b and
RXR a expression vectors. The electrophoretic mobility of the
radiolabelled DNA fragments was retarded in presence of
nuclear extract suggesting possible interaction between the
32P-
l a b e l e dD N Af r a g m e n t sa n dT R sp r e s e n ti nt h en u c l e a re x t r a c t .
This binding was later confirmed by competition with 50 and
100 fold molar excess of cold self oligos, mutated and non
specific oligos as shown in Fig.2 A, B. The mobility was further
retarded in presence of anti hTRb antibodies as shown in Fig. 2
A, C, D, E but there was a clear reduction in the intensity of
the TR/DNA complex upon addition of anti-TRa and anti
RXRa a n t i b o d i e s .W h e nw ew e r ea d d i n ga l lt h ea n t i b o d i e s
TRa,T R b and RXRa together greatly diminished the major
protein-DNA complex with a clear shift of band as shown in
lane 7 of Fig. 2D and E. Moreover, the binding affinity of TRs
to these labelled oligos of two binding sites was also decreased
in presence of T3 hormone as shown in Fig. 3A. This result was
further confirmed in Chromatin immunoprecipitation (ChIP)
assays as in Fig. 3B. The above results clearly indicated that
SMP30 promoter has specific binding sites for TRs.
SMP30 Promoter in response to T3
We examined the response of T3 on transcriptional activity of
hSMP30 promoter in MCF-7 cells by measuring luciferase activity.
We transfected reporter constructs having an oligo representative
of the TREs appended to some minimal promoter along with or
without expression vectors in MCF-7cells. The minimal promoter
(2684 to 2455) region cloned in PGL3 basic vector is known as
hSMP30 TRE1 and cloned (21290 to 21015) promoter fragment
is known as hSMP30 TRE2. Luciferase activity of both the
reporter vectors in MCF-7 cells having endogenous TRs did not
show any significant difference in presence or absence of T3 where
as luciferase activity was induced by over expressing TRs along
with RXRa in absence of ligand and repressed in presence of
ligand as shown in Fig 4A, B. However there was no repression
found in overexpressing only RXRa by T3 treatment as presented
in Fig. S2. Similar results were obtained using other cell line such
as HEK 293 cells (as Fig.S3). The SMP30 promoter behaved
similarly to those of TSHa [45], SOD1 gene [46], Necdin gene
[47] which are negatively regulated by T3. These observations
suggested that the TREs on SMP30 promoter were negatively
regulated by T3.
The total luciferase expression of mutated construct of hSMP30
TRE2 (in the presence and absence of T3) was decreased as
compared with wild type and the changes in the repression ratios
were also small as compared with those noted with the wild type
shown in Fig.4C. However, mutated hSMP30 TRE1 did not show
the similar pattern. Repression was still observed although de-
creased luciferase activity was detected in Fig.4D. These results
indicated that high affinity TR binding TREs were not necessary
for T3 mediated negative regulation of SMP30 gene similar to ear-
lier observation in case of some other genes i.e CD44 gene [48],
hTSHb [49], RSV nTRE [50,51].
To analyze the effect of TRs on hSMP30 TREs by estradiol (E2)
stimulation, we did luciferase assays of hSMP30 TREs in presence
and absence of E2. We found ligand independent or dependent
activation of promoter activity in case of both hSMP30 TRE1 and
TRE2.However, in case of thyroid hormone treatment there was
downregulation of luciferase activity as shown in Fig. 4E and F.
Figure 1. Downregulation of SMP30 gene in MCF-7 cell line by 3, 395 triiodo L thyronine. (A) Representative Western blot of total SMP30
protein in response to overnight treatment with T3 in MCF-7 cells. (B) Expressional analysis of SMP30 gene after overnight T3 treatment to TRs or TRs
and RXRa cotransfected MCF-7 cells in Fig.1B was performed by Western blot analysis. 100 mg of protein from whole cell extract was used for Western
analysis.In all figures (1A and B) SMP30 protein was detected by SMP30 antibody at ,30 kDa, TRb protein was detected by TRb antibody at 58 kD,
TRa protein was detected by TRa antibody at 55 kD and RXRa protein was detected by RXRa antibody at 54 kD were assessed. a-Tubulin was used as
a loading control. In Fig. 1C and D, total RNA from cells were harvested and analyzed by quantitative RT-PCR. Shown are the mean values from
triplicate samples normalized to GAPDH. CT values obtained from the real time PCR was used to compare the expression label of treated sample from
control assuming 100% amplification. Paired student’s t test performed; *, P,0.01 results were confirmed in three independent experiments as in
Fig. 1C. *** P,0.0001difference from control using ANOVA as in Fig. 1D.
doi:10.1371/journal.pone.0020861.g001
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TRE2 in MCF-7 cells having endogenous TRs did not show any
significant difference in presence or absence of T3 where as lucif-
erase activity was induced by over expressing TRa in absence or
presence of ligand. However there was significant repression found
while overexpressing only TRb in presence of ligand as presented
in Fig.4G and H. These results indicate that hSMP30 promoter
responds to exogenous expression of TRb and this effect is syner-
gized by T3 through further repressing the promoter activity.
Effects of the HDAC inhibitor TSA, on T3 mediated
hSMP30 repression
T3 is known to recruit HDACs to the thyrotropin releasing
hormone (TRH) and thyroid stimulating hormone TSH b
promoters during ligand dependent negative regulation. Hence,
histone deacetylation may also be an important mechanism for the
negative regulation of other target genes by T3 [32 and 52].
We therefore examined the effects of the histone deacetylase
inhibitor TSA, on T3 mediated SMP30 repression in MCF-7 cells
by referring the following papers [32,47]. The ligand dependent
and independent transcriptional activation of the SMP30 reporter
construct was abolished when TSA was added as shown in Fig 5A,
B.
Effect of TSA on SMP30 gene expression in MCF-7 cells was
analysed both at RNA and protein level by RT-PCR and Western
Blot analysis in Fig. 5C, D and E. T3 treatment resulted in
repression of SMP30 gene expression by 40% and TSA further
repressed SMP30 expression by 20% as here in Fig. 5E. These
results suggested that T3 dependent histone acetylation of SMP30
promoter has an important role in regulation of SMP30 gene
Figure 2. Identification of high affinity TR binding sites within hSMP30 Promoter. (A) Electrophoretic mobility shift assay for hSMP30 TRE1
to confirm the binding of TR. lane 1, labeled hSMP30 TRE1; lane 2, 7 are labeled hSMP30 TRE1 with 10 mg of Nuclear Extract (N.E.); lane 3–6 describe
competition with 100 fold molar excess of self oligo, 50 and 100fold molar excess of mut TRE1 oligo, nonspecific oligo and lane 8 antibody shift with
TRb antibody. (B) Electrophoretic mobility shift assay for hSMP30 TRE2 to confirm the binding of TR. Lane 1, labeled hSMP30 TRE2 with 10 mg nuclear
extract (N.E); Lane 2–4 describe competition with 50 and 100 fold molar excess of self oligo and mutated TRE2 oligo. (C) As antibody shift was not
distinct for short run i.e. for 1 hour, we did long run for two hours, then we got distinct antibody shift in fig. 2C. Lane 2 and 3 are labeled hSMP30
TRE1 and TRE2 with 10 mg N.E; Lane 1 and 4 are antibody shift with TRb antibody. (D, E) To confirm the binding of TRb is specific to hSMP30 TRE1 and
TRE2, we did electrophoretic mobility shift assay in presence of control IgG, TRa,T R b and RXRa antibodies. Lane 1 labeled hSMP30 TRE1 and TRE2;
lane 2 labeled hSMP30 TRE1 and TRE2 in presence of 10 mg of N.E of MCF-7 cells - transfected with TRa,T R b and RXRa expression vectors; lane 3, 4, 5,
6 antibody shift with TRa, normal Rabbit IgG, RXRa and TRb respectively; lane 7 labeled hSMP30 TRE1 and TRE2 in presence of 10 mg of N.E incubated
with TRa,T R b and RXRa antibodies in a single reaction. Arrows indicate retarded and supershifted complexes.
doi:10.1371/journal.pone.0020861.g002
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affect T3 dependent silencing of transcription of the SMP30 pro-
moter, but instead was involved in the ligand independent acti-
vation, thus reinforcing the differences in the mechanisms behind
TR dependent transcriptional regulation of negative thyroid res-
ponse element (nTREs) vs positive thyroid response element
( pTREs).
Recruitment of Cofactors to SMP30 promoter after T3
treatment
We next investigated the cofactors that participated in the T3-
dependent histone acetylation of SMP30 promoter by ChIP analysis
(Fig.6). It was found that TRb can bind to SMP30 promoter
irrespective of the presence or absence of T3, but its binding affinity
was decreased in the case of former. Here we have measured the
binding affinity of thyroidreceptor to SMP30 promoter as a result of
changes in the steady state level of the TR bound to DNA across a
population of cells. The above finding suggested that interaction of
unknown thyroid receptor associated proteins to thyroid receptor
bound to negative thyroid response elements were required for the
cooperative repression. We examined the recruitment of different
cofactors like HDAC3, HDAC2, HDAC1, NCoR and Steroid re-
ceptor coactivator (SRC-1) to nTREs by ChIP assays (Fig.6A).
Location of primers used in ChIP assays are shown in Fig. 6B.
Quantitative real-time PCR of ChIP products were used to com-
paretheamplificationofboundDNAbydifferentantibodiessample
from input control assuming 100% amplification was shown in
Fig.6C and D. There was no further recruitment of HDAC3,
HDAC2, NCoR, and HDAC1 on SMP30 promoter after T3
treatment. However, bindingof SRC-1increased with T3 treatment
on hSMP30 TRE2 butthesamewasdecreasedin hSMP30TRE1 in
accordance with the reduced binding of TRb to SMP30 TREs. But,
affinity of SRC-1 to bind TRb was found to increase with T3
treatment as shown in Co Immunoprecipitation (CoIP) Fig. 7A, B.
The above observations indicate that histone acetylation of SMP30
promoter after T3 treatment involves SRC-1 recruitment.
TRb enhances TR- mediated Basal Transactivation of the
SMP30 Gene
Among the two known isoforms of thyroid receptor, TRb is
reported to play a determining role in negative regulation of genes
by thyroid hormone [53]. Therefore we examined the role of TRb
in the observed negative regulation of SMP30 gene by T3. Co-
transfection of hSMP30 TRE1 and hSMP30 TRE2 luciferase con-
struct with TRs and RXRa expression vectors resulted in increased
basal transactivation of SMP30 gene in absence of T3. However, in
presence of T3 the promoter activity of SMP30 returned to basal
level. siRNA mediated silencing of TRb, completely abolished the
basal transactivation of SMP30 (Fig. 8A, B). T3 dependent re-
pression of SMP30 was released in cells transfected with siTRb.This
result was further confirmed by Western blot analysis. There was
(Fig. 8C) slight increase in SMP30 protein expression in the cells
transfected with siTRb compared to scrambled siRNA transfected
control cells indicating an important role of TRb in T3 mediated
negative regulation of SMP30.
Effects of histone acetyl transferase (HAT) inhibitor on
SMP30 promoter transcriptional activity
Our ChIP results using antibodies against histone acetylated
lysine at 18position (H3K18) revealed histone acetylation of SMP30
promoterwasincreased afterT3 treatment.T3 causesan increase in
acetylation of H3K9 and H3K18 but does not affect acetylation of
H3K14 where as H3K27 is deacetylated after T3 treatment [54].
An overall increase in acetylation of H3 leads to negative regulation
of TSHa promoter [54]. Our specific finding of distinct recruitment
of SRC-1 onTRE2 due to the enhanced association of SRC-1with
TRb in response to T3 signaling as evidenced in Co-IP experiments
made out a definitive mechanism behind the repression of SMP30
gene expression. Distinct withdrawal of SRC-1 from TRE1 sup-
ports for the possibility that another cofactors with HAT activity
may participate in the negative regulation of SMP30 gene expres-
sion.To further examine the roleofcoactivatorSRC-1 inmediating
negative regulation, we examined the effects of HAT inhibitor
CPTH-2- [cyclopentylidiene-[4-(49- chlorophenyl) thiazol-2-yl)hy-
drazone] on SMP30 promoter transcriptional activity. CPTH-2, a
known modulator of Gcn5 network [55] increased basal transcrip-
tion levels in presence and absence of T3, presumably by decreasing
histone acetylation as shown in (Fig.9A, B, C and D). These results
provide further evidence for the importance of coactivator SRC-1
recruitment in mediating negative regulation of the SMP30 gene
even though basal levels may be determined by overall histone
acetylation.
Hormonal repression of SMP30 induces apoptosis in
MCF-7 cells
Finally, we investigated whether induction of apoptotic death in
MCF-7 cells by thyroid hormone is mediated through down
Figure 3. Effects of T3 on TR-DNA interaction. (A) Electrophoretic
mobility shift assay for hSMP30 TRE 1 and 2 in presence of T3 hormone.
Lane1,4arelabeledhSMP30TRE1and2respectively.Lane2,5arelabeled
TREs with 10 mg of N.E., Lane 3, 6 are labeled TREs with 10 mgo fN . Ei n
presence of 1 mMT 3 hormone. (B) TRb binding to SMP30 promoter is
affected by T3 treatment was shown in ChIP. After 1 hr. treatment with
1 mMT 3, MCF-7 cells were crosslinked with 1% formaldehyde and ChIP
assays were performed according to manufacturer’s protocol (Upstate
Biotechnology) with some minor modifications. After reverse crosslinking
byheatingthe samples at65uC for 4–6 hrs andtreating withproteinase K,
DNA was elute by phenol chloroform extraction then ethanol precipita-
tion. PCR was performed to visualize the enriched DNA fragments. In vivo
association of TRb protein complex with the hSMP30 promoter was
demonstrated by the amplification of hSMP30 TREs specific DNA
fragments from chromatin complexes precipitated by antibodies for TRb.
doi:10.1371/journal.pone.0020861.g003
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thyroid hormone treatment enhanced the proportion of MCF-7
cells undergoing apoptosis by 50–60% (Fig.10). Overexpression of
SMP30 in MCF-7 cells lowered the proportion of apoptotic cells
below the basal level (Fig. 10A, C) and knocking down of
endogenous SMP30 further enhanced the induction of apoptosis
by 20–30% (Fig. 10B, D). Further, Western blot analysis revealed
that cleavage of, Poly (ADP Ribose) Polymerase (PARP) an
indicator of caspase activation in SMP30 siRNA transfected thy-
roid hormone treated cells was more in comparison to untreated as
well as only thyroid hormone treated cells (Fig. 10D). Similarly,
PARP cleavage was found to decrease in SMP30 transfected
thyroid hormone treated cells compared to only thyroid hormone
treated cells (Fig. 10C). Taken together, the above results clearly
suggest that down regulation of SMP30 has an important role
during thyroid hormone induced apoptosis in MCF-7 breast
cancer cells.
Discussion
Recent findings indicate that epigenetic alterations of the ge-
nome such as acetylation/ deacetylation and other modifications
of histones prove to be key factors in breast carcinogenesis [56].
These modifications are quite interesting as targets from therapeu-
tic point of view. Various studies have established that deregula-
tion of hormonal signaling can be correlated to notable epigenetic
alterations [57]. The proapoptotic potential of the thyroid hor-
mone has been advocated with evidence by several research
findings. [34, 35 and 36]. MCF-7 cells represent one of the few
well defined breast cancer cell lines with endogenous expression of
TRs [25]. Interestingly, in MCF-7 cells we observed substantially
good amount of expression of SMP30 which is well established as
an anti-apoptotic gene. The responsiveness of SMP30 gene to T3
signaling has been reported in an investigation in mouse model
[42]. Another recent study demonstrated negative regulation of
Figure 4. SMP30 Promoter in response to T3. Transient transfections of hSMP30 TRE1, TRE2 (A, B, E, F, G, H) and mut hSMP30 TRE1 and TRE2 (C,
D) were carried out using MCF-7 cells and similar experiments were also carried out in HEK 293T cell line as shown in Fig.S3. 20 hrs before
transfection, cells were plated in DMEM 10%CS media, at a density of 1610
5 cells per well in 12 well plates. For transient transfection, 0.5 mgo f
reporter plasmid DNA, 0. 5 mgo fT R b and TRa (TRs), RXRa expression vector or pCMV vector in (A,B,C,D,E,F) , 0.5 mgo fo n l yT R b or TRa expression
vector or pCMV vector in (G, H) ,50 ng of pRL-TK control vector were co transfected using Fugene HD transfection reagent (from Roche) as per
manufacture’s instruction. After 2 4hrs of transfection, cells were subjected to overnight treatment with 1 mM concentrations of T3 (A, B, C, D, G, H),
10 nM of E2, 1 mM of T3 or ethanol vehicle to cells (E, F) in 10% CS –DMEM. Then cell lysates were prepared and luciferase activities were measured.
Values are the mean of three independent experiments 6 SD normalized to Renilla activity. * P,0.0232 difference from control using ANOVA for
Fig A, *** P,0.0001difference from vehicle control using ANOVA in Fig. B, C, D, E, F and G, ** P,0.001difference from vehicle control using ANOVA
in Fig. H.
doi:10.1371/journal.pone.0020861.g004
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above findings in our current approach, we decided to use MCF-7
as a model cell line of breast cancer to study the effect of thyroid
hormones with reference to SMP30 gene.
In the current study our investigation by flow cytometry re-
vealed that in response to thyroid hormone treatment, apoptosis
could be induced in MCF-7 cell line as a result of down regulation
of SMP30 gene expression. In an effort to unravel the underlying
mechanism, we performed primer extension analysis to find out
the transcription start site of human SMP30 (hSMP30) gene,
scanning of hSMP30 promoter for TRE sites followed by gel
retardation assays. On the basis of these experiments we confirmed
that there are two important putative TREs at 613 bp as (hSMP30
TRE1) and 1.2 kbp (hSMP30 TRE2) from hSMP30 transcription
start site. The luciferase assays which were conducted by taking
different deletion constructs of hSMP30 promoter validated our
findings of the putative TRE sites. Looking at the distinct repres-
sion caused by liganded TRs (through T3) in Fig. 1, we interpreted
that activated TRs play a significant role in downregulating hu-
man SMP30 gene. Similar to our line of study, Guigon et al (2011)
have identified STAT-5 as a downstream key molecule in the
aberrant thyroid hormone signaling emerging out of mutated
TRb. As the consequence of this the mice is predisposed to de-
velopment of mammary tumors [23]. T47D human breast cancer
cell line which is also ER+ve has been used in the above studies. In
their investigations remarkable repression of reporter vectors as
well as protein were obtained by exogenously transfected TRb like
others similar interesting study. In our current study also
significant repression of reporter vectors as well as SMP30 protein
were observed by transfecting TRb. These results indicated that
Figure 5. Effects of the HDAC inhibitor TSA, on T3 mediated hSMP30 repression. (A, B)After 24 hrs of transfection as described above, cells
were subjected to overnight (1 mM) T3 treatment followed by 6 hrs incubation in 330 nM of TSA or ethanol vehicle to control cells. Cell lysates were
prepared and luciferase activities were measured. Values are the mean of three independent experiments 6 SD normalized to Renilla activity.
*** P,0.0001difference from vehicle control using ANOVA in Fig. A and B. (C, D, E) Expressional analysis of SMP30 gene after T3 and TSA treatment to
MCF-7 cells was analysed by RT-PCR, Western blot analysis and real time PCR. RT-PCR and Real time PCR were preformed as described previously.
Western blot analysis was carried as described previously. In Fig. C, SMP30 protein (upper panel) band at ,30 kDa was detected by SMP30
antibody.a-Tubulin (lower panel) was used as a loading control. A representative RT-PCR data has shown in Fig. D. SMP30 gene (left panel) and
GAPDH gene in (right panel) using cDNA from MCF-7 control cells, T3 treated and T3+TSA treated cells. Same cDNA was used for quantitative RT-PCR
as in Fig. E. Shown are the mean of triplicate samples (mean 6 SD) normalized to GAPDH. CT values obtained from the real time PCR was used to
compare the expression label of treated sample from control assuming 100% amplification. Results were confirmed in three independent
experiments. ** P,0.0029 difference from control using ANOVA.
doi:10.1371/journal.pone.0020861.g005
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of T3, possibly by stabilizing interaction with other intermediary
factors. But it may be noted with emphasis that it is not important
for T3 dependent repression of SMP30 transcription. The above
findings revealed that hSMP30 promoter responds to exogenous
expression of TRb and this effect was synergized by T3 through
further repressing the promoter activity. Silencing of TRb in
MCF-7 cell line reduced the amount of repression as a result of T3
treatment both in terms of protein as well as promoter activity.
The total luciferase expression of mutated construct of hSMP30
TRE2 (in the presence and absence of T3) was decreased as
compared with wild type and the changes in the repression ratios
were also small as compared with those noted with the wild type.
From this it is quite clear that the decrease in the repression might
be due to decrease binding affinity of mutated TREs with TRs.
However, mutated hSMP30 TRE1 did not show the similar pat-
tern. Repression was still observed although decreased luciferase
activity was detected. In summary, these results indicated that high
affinity TR binding TREs were not necessary for T3 mediated
negative regulation of SMP30 gene. In literature one hypothesis
suggests that indirect involvement of TR in T3 mediated negative
regulation is through the squelching of coregulators from other
Figure 6. Recruitment of Cofactors to SMP30 promoter after T3 treatment. (A) Corepressor complex and coactivator binding to minimal
SMP30 promoter fragment having TREs and of the control regions having non TREs were analysed by ChIP assays. MCF-7 cells were crosslinked with
1% formaldehyde after 1 hour addition of T3, and ChIP assays were performed according to manufacturer’s protocol (Upstate Biotechnology) with
some minor modifications. After reverse crosslinking by heating the samples at 65uC for 4–6 hrs and treating with proteinase K, DNA was elute by
phenol chloroform extraction then ethanol precipitation. In vivo association of theses protein complexes with the hSMP30 promoter was
demonstrated by the amplification of hSMP30 TREs specific DNA fragments from chromatin complexes precipitated by antibodies for TRb, HDAC3,
HDAC2, HDAC1, NCoR, anti-acetyl H3 antibody(H3K18) and SRC-1. Specific primers for detection of respective regions (TRE1, 2744 to 2324; TRE2,
21407 to 21094; non TRE, 2344 to +67) were represented. Similar results were obtained in multiple independent experiments. (B) Diagram of
human SMP30 promoter and location of primers in ChIP assays. Two thyroid response elements are located at 2604 and 21244 position of hSMP30
gene from transcription start site (TSS). The upstream primer (1F1) for TRE1 started at 2743 bp and the downstream primer (Xho2R) started at 2324
from TSS of hSMP30 gene. The forward primer (3F1) of TRE2 started at 21407 bp and the reverse primer (2R2) started at 21094 bp from TSS of
hSMP30 gene. Primers denoted by arrows and name of each primer are written within a box. CAAT represent the CAAT box. (C, D) Quantitative real-
time PCR of ChIP products were carried out by taking same sets of primers as conventional PCR and confirmed that the set of the primers for the real-
time PCR yielded a single peak in the 40-cycle procedure. CT values obtained from the real time PCR was used to compare the amplification of bound
DNA by different antibodies sample from input control assuming 100% amplification. Values are the mean (mean 6 SD) normalized to input levels
were compared with those obtained with IgG for at least three independent experiments. ***P,0.0001 difference from control using ANOVA.
doi:10.1371/journal.pone.0020861.g006
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observations made in the studies of T3 mediated negative re-
gulation of different genes like CD44 [48], hTSHb [49], RSV
nTRE [50,51]. The results of the experiments, carried out with
estrogen signaling, further confirmed our claim that the repression
of SMP30 is T3 specific.
The supershift assay performed in presence of TRa,T R b and
RXRa antibodies indicated that TRb has direct binding affinity
for both TRE1 and TRE2. However, it might be possible that
TRa,T R b and RXRa protein forms a heterodimer complex then
binds to thyroid response elements of both the sites present in
hSMP30 promoter.
On the basis of our results we interpreted that thyroid response
elements cannot be categorically classified as absolute positive or
absolute negative elements. However by considering acetylation of
histone i.e H3 as bench mark for the above classification we
concluded that both TRE1 as well as TRE2 in SMP30 promoter
are negative response element in the context of liganded TRs. By
observing both the TREs differentially regulated by TRs we would
like to further distinguish them on the basis of different cofactors
recruitment on those TREs after T3 treatment. Our specific
finding of distinct recruitment of SRC-1 on TRE2 due to the
enhanced association of SRC-1with TRb in response to T3 sig-
naling as evidenced in [46] and also shown in Co-IP experiments
made out a definitive mechanism behind the repression of SMP30
gene expression. Distinct withdrawal of SRC-1 from TRE1 sup-
ports the possibility that another coregulator/s with HAT activity
may participate in the negative regulation of SMP30 gene ex-
pression. Previous studies in SRC-1 knockout mice and TRb
activation function-2 domain mutant knock in mice suggest that
coactivators may be important for negative regulation of genes
[58, 59, 60 and 61]. In our investigation another interesting but
opposite result was observed in the recruitment pattern of
HDAC1, HDAC2 as well as NCoR on TRE1 and TRE2. These
differential recruitment patterns also make our above argument
more logical. Similar kinds of observations were reported for
SOD1, Necdin, and CD44 - target gene that they are under
negative regulation by T3 [46, 47 and 48]. We believe enhanced
recruitment of AcH3 locally does not speak for the complete active
chromatin structure. The recent reports by Wang et al [45,54]
about TSHa target gene also de-link the traditional concept of
enhanced histone acetylation to transcriptional activation of the
gene. The above cited investigation also explained our findings of
further repression of SMP30 gene by TSA (Trichostatin A) which
is an inhibitor of deacetylases. The repression of SMP30 gene by
liganded TRs was reversed after treatment with HAT inhibitor.
From this observation it was very clear that histone acetylation
played a major role in the negative regulation of SMP30 gene by
liganded thyroid receptor. It also established the authenticity and
importance of our characterisation of two negative thyroid res-
ponse elements i.e TRE1 and TRE2 of SMP30 promoter. These
observations resemble the functioning of other liganded TR
mediated negative TREs (nTREs) [30]. In the above investigation
Tagami et al discussed that TR mediated recruitment and basal
activation by SMRT and NCoR in absence of T3 and reversal of
basal activation by dissociation of corepressors in the presence of
T3 [30]. On the background of these contrasting results, we
advocate that the response of SMP30 promoter to T3 signaling
may not be analysed in isolation with regard to either TRE1 or
TRE2. Rather the repression of SMP30 gene expression is the
combined outcome of the response of both the above elements to
T3 signaling.
Observations in the present study revealed that thyroid
hormone mediated down regulation of SMP30 was direct and
accomplished through negative TREs within hSMP30 promoter.
To ascertain the role of SMP30 in the thyroid hormone induced
apoptosis of MCF-7 cells, we studied the effect of thyroid hormone
after overexpressing and knocking down the SMP30 gene in
MCF-7 cells respectively. Overexpression of SMP30 in our study
resulted in reversal of thyroid hormone induced apoptosis of
MCF-7 cells while knocking down of SMP30 made the cells
increasingly susceptible to thyroid hormone induced apoptosis.
These findings indicated anti-apoptotic role of SMP30 in MCF-7
cells which is in accordance with earlier reports regarding the role
of SMP30 in literature [38–41] in other systems. We found out
that apoptosis can be executed by downregulating the expression
of SMP30 gene in MCF-7 cells. Interestingly, this repression was
further enhanced as a result of T3 as well as TSA treatment. It is
a well established fact that TSA which is a HDAC inhibitor
induces apoptosis in different types of cancer [62]. It has also been
reported that TSA induced apoptosis in lymphoma cells by
decreasing Bcl-2 expression significantly [63]. Overexpression of
HDACs increases Bcl-2 expression and inhibition of HDAC
activity by HDAC inhibitor decreases its expression [63]. In the
specific case we would like to bring several reports about the
hypothesis and established finding about the negative thyroid
response elements. It has been reported that TSA can inhibit the
transcriptional activation of the mouse mammary tumor virus
promoter by progesterone, suggesting histone acetylation is not
always correlated with increased transcription [64]. Wang et al
[45] suggested that there is a subset of thyroid hormone mediated
negatively regulated genes with increased histone acetylation by
microarray analysis. Because of lack of unequivocal evidence
correlating TRb with mammary tumor development a concrete
Figure 7. Effects of thyroid hormone on endogenous protein
complexes were detected by Co-immunoprecipitation. (A, B)
MCF-7 cells were plated in10%CS DMEM, next day cells were subjected
to overnight (1 mM) T3 treatment. One hundred microgram of whole cell
extracts were resolved in SDS-PAGE followed by Western blot analysis
as shown in Fig.4E. In Fig.4F, 500 mg of whole cell extracts were
precipitated with TRb, SRC-1 and with normal IgG antibodies. Then
precipitated proteins were eluted from protein A/G plus sepharose
beads separated by SDS-PAGE, and analyzed by Western blotting (WB).
Asterisks denote IgG heavy chain band in upper panel and IgG light
chain band in lower panel.
doi:10.1371/journal.pone.0020861.g007
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Similar to our line of observation Guigon et al (2011) have shown
downregulation of STAT-5 as a result of mutation in TRb which
was manifested in terms of predisposal of the mice to the de-
velopment of mammary tumors. Our current study and the
emerging importance of thyroid hormone in breast cancer support
our claim that why we need to seriously think for a combinatorial
therapy by taking both T3 as well as other anticancer drugs
including those related to TSA [65]. Additionally, downstream
target molecules also need to be identified and thoroughly
investigated for their role in inducing apoptosis or development
of mammary gland tumor as a result of variable or aberrant thy-
roid hormone signaling. Our current study may prove to be useful
for developing potent therapeutic agent to challenge the pro-
gression of breast cancer.
Materials and Methods
Cell Culture
MCF-7and HEK 293T were obtained from National Centre for
Cell Sciences, Pune. They were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS) mantained in 5% CO2
atmosphere in 37uC until 70–80% confluent. For stimulation with
T3, culture medium was removed, the cells were rinsed once with
phosphate buffer saline (PBS) and medium containing10% char-
coal-stripped fetal bovine serum (CS-FBS) was added and
incubation continued for 3 days. T3 (1 mM), (from Sigma) was
diluted in medium and charcoal-stripped 10% fetal bovine serum
was added to cells for the times indicated in figure legends.
Plasmid Constructions
hSMP30 TRE1 reporter construct was prepared by amplifying
human SMP30 promoter from MCF-7 genomic DNA by using
hSMP PCR 1F2 and hSMP PCR 1R1 primer sequences are shown
in table 1. That amplified product, then cloned into pBlue TOPO
TA vector (Invitrogen). Insert was taken out from pBlue TOPO
TA vector by HindIII digestion and ligated in to HindIII digested
PGL3 Basic vector to obtain hSMP TRE1 reporter construct.
Similarly, hSMP TRE2 reporter construct was prepared by
amplifying human SMP30 promoter from MCF-7 genomic DNA
using hSMP PCR 2F and hSMP PCR 2R1 primer sequences
shown in table 1and then cloned in to pTARGET
tm vector. Insert
was taken out from pTARGET
tm vector by digesting in Kpn I and
Xho I enzyme, ligated in to digested PGL3 basic vector. RT-PCR
product of human SMP30 was prepared from MCF-7 cDNA by
using hSMP30 EcoRI F and XhoI R primers (sequences are shown
in table 1). Then that product was ligated in to digested pCMV
vector using DNA ligase to make SMP30 expression vector.
pCMX-hRXR-a, pCMX-hTRb and pCMX-rTRa were received
from Dr Ronald M Evans, The Salk Institute for Biological
Studies, San Diego, CA. All constructs were confirmed by manual
sequencing.
Transfection and Luciferase Assay
Transient transfections were carried out using MCF-7 cells and
similar experiments were also carried out in HEK 293T cell lines.
20 hrs before transfection, cells were plated in DMEM 10%CS
media, at a density of 1610
5 cells per well in 12 well plates. For
transient transfection 0.5 mg of reporter plasmid DNA, 0.5 mgo f
Figure 8. TRb enhances TR- mediated Basal Transactivation of the SMP30 gene. (A, B) hSMP30 TRE1 and TRE2 reporter constructs were
transfected in MCF-7 cells. 24 hrs after transfection of reporter plasmid DNA and expression vectors, 200pmole per well of TRb siRNA or non specific
scrambled siRNA (syntesized from Eurogentec) were transfected using oligofectamine according to manufacture’s instruction (Invitrogen). After 24 hrs
of second round transfection, cells were incubated for an additional 24 hrs in the presence and absence of 1 mMT 3, then cells were harvested for
luciferase assays andreadings were takenin duplicates in three independent experiments. Values arethe mean of three independent experiments 6 SD
normalized to Renilla activity. *** P,0.0001 difference from control using ANOVA. (C) The endogenous SMP30 expression was measured in TRb
knockdown MCF-7 cells by Western blot analysis. Decrease of TRb expression by TRb siRNA transfection was confirmed by Western blot analysis.
Western blot analysis was carried by taking equal amount of protein from scrambled siRNA or siTRb transfected MCF-7cells. SMP30 protein (upper
panel) at ,30 kDa, TRb protein (middle panel) at ,58 kDa was detected by TRb antibody and a-Tubulin (lower panel) was used as a loading control.
doi:10.1371/journal.pone.0020861.g008
Downregulation of SMP30 by T3 Induces Apoptosis
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20861TRb and TRa as (TRs), RXRa expression vector or pCMV
vector and 100 ng of pRL-TK control vector were co transfected
using Fugene HD transfection reagent (from Roche) as per
manufacture’s instruction. After 24 hrs of transfection 1 mMT 3
hormone was added and treatment of TSA and HAT inhibitor
(from Sigma) were carried out accordingly as shown in figure
legend. The cell lysates were prepared, and luciferase activities
were measured in duplicates in three independent experiments.
Transient Transfection of siRNA
24 hrs after transfection of reporter plasmid DNA and expres-
sion vectors, 200pmole of TRb siRNA or nonspecific scrambled
siRNA (syntesized from Eurogentec) per well were transfected
using oligofectamine according to manufacture’s instruction (In-
vitrogen). After 24 hrs of second round transfection, cells were
incubated for an additional 24 hrs in the presence and absence of
1 mMT 3, then cells were harvested for luciferase assays and
readingsweretakenin duplicates inthree independent experiments.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assay was performed as described
in [66]. Oligonucleotides (both strands) corresponding to hSMP30
TRE sites were synthesized as shown in table 2. For each site one
strand was end labelled with c
32P ATP using T4 poly nucleotide
kinase and annealed to its complementary unlabelled strand.
Nuclear extracts of MCF-7transfected with TRa,T R b and RXRa
expression vectors (10 mg) to maintain appropriate concentration
of functionally active nuclear receptors were incubated with
20fmoles of radiolabelled oligonucleotide duplex and 1 mg poly (d
I-d C) in 30 ml reaction mixture containing 10 mM Tris-HCl
(pH 7.5), 50 mM NaCl, 1 mM DTT, 5% glycerol for 20 mins at
room temperature. In competition experiments, 100fold molar
excess of unlabeled self and mutated oligonucleotide duplexes
(sequences as shown in table3) were added during pre incubation
period. For antibody shift assay, control IgG (Santacruz), TRa
(Abcam), TRb(Abcam), RXRa (Santacruz) antibodies were added
after addition of nuclear extract and probe, followed by incubation
for 45 mins at room temperature. Free DNA and protein bound
DNA was separated in 5% non-denaturing polyacrylamide gel in
0.5x TBE. After electrophoresis, gels were blotted on to filter
paper, dried and autoradiographed.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assay was performed as previously described [67]. Briefly,
MCF-7 cells were grown to 90% confluence in DMEM sup-
plemented with 10% charcoal stripped fetal bovine serum for
3days. After addition of 1 mM T3 for 1 hour, ChIP assays were
performed according to manufacturer’s protocol (Upstate Bio-
technology) with some minor modifications. After reverse cross-
linking by heating the samples at 65uC for 4–6 hrs and treating
with proteinase K, DNA was elute by phenol chloroform extrac-
tion then ethanol precipitation. PCR was performed to visualize
the enriched DNA fragments using primers that amplify hSMP30
TRE1 (h SMP PCR 1F1 and Xho2 R), TRE2 promoter (h SMP
PCR 3F1 and 2R2) and non TRE region. These primer sequences
were listed in table 4. Conventional PCR signals stained with
ethidium bromide in 2% agarose gel as shown in Fig. 6A.
Co-immunoprecipitation assays
Co-Immunoprecipitation (Co-IP) and western blot assays were
performed as described [68]. Five hundered micrograms of MCF-
7 whole cell extracts were subjected to immunoprecipitation (IP)
with the indicated antibodies as shown in Fig.7B and the precip-
itated protein complexes were subjected to Western blot analysis.
Real-time PCR
MCF-7 cells were harvested after 15 hrs of T3 followed by 6 hrs
of TSA with or without treatment. RNA was isolated and SMP30
and GAPDH mRNA expression were determined by quantitative
RT PCR using SYBR greensystem (SIGMA). Relative values
(mean 6 SD) normalized to GAPDH expression.
RT PCR
RT-PCR was preformed as described elsewhere [42]. The
sequences of sense and antisense primer for hSMP30 were given in
table 5. As a positive control, a fragment of human GAPDH
cDNA was amplified by using primers were given in table 5. The
PCR condition for SMP30 was as follow: initial denaturation
(94uC 3 min), (94uC4 5s ,6 5 uC4 5s ,7 2 uC 45 s) for 30 cycles and
Figure 9. Effects of HAT inhibitors on SMP30 promoter
transcriptional activity. (A) Effects of HAT inhibitor on acetylation
of SMP30 promoter (hSMP30 TRE1 and hSMP30 TRE2) was carried out by
ChIP assays using anti-acetyl H3 antibody (H3K18). MCF-7 cells were
treated with CPTH2 for overnight followed by 1 mMo fT 3 treatment for
1 hr before harvesting for ChIP assays. (B) SMP30 transcriptional activity
after blocking with HAT inhibitor, CPTH2. Transfection of hSMP30TRE1
and TRE2 reporter vectors along with expression vectors were carried
out as described above followed by overnight treatment with 1 mMo f
T3 and 0.05 mM concentrations of CPTH2 (24 hr post transfection). Then
cell lysates were prepared and luciferase activities were measured.
Values are the mean of three independent experiments 6 SD
normalized to Renilla activity. ***P,0.0001 difference from vehicle
control using ANOVA.
doi:10.1371/journal.pone.0020861.g009
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PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e20861Figure 10. Hormonal repression of SMP30 induces apoptosis in MCF-7 cells. (A, B) Apoptosis was assessed by flow cytometry. MCF-7 cells
transfected with mock vector (CMV-FLAG) and vector containing SMP30 gene as (SMP30-FLAG) were incubated in presence or absence of 10 mMT 3
for 24 hrs in culture. Knocking down of endogenous SMP30 expression or scambled siRNA transfected control MCF-7 cells were followed by
incubation with or without 10 mMT 3. After 24 hrs of incubation cells were harvested and assayed for apoptosis using the Annexin V FITC apoptosis
detection kit, IMGENEX according to manufacturer’s instruction. Cells were analyzed in FACS Calibur Analyzer (Becton Dickinson) by using Cell Quest
Pro software. Shown are the mean of triplicate samples 6 SD normalized to control. Similar findings were found in two other experiments,
***P,0.0001 difference from only vector transfected control using ANOVA in Fig. 6A and***P,0.001difference from scrambled siRNA transfected
control using ANOVA in Fig. 6B. (C, D) Detection of apoptosis was further confirmed by flow cytometry analysis of intracellularly stained MCF-7 cells
with PE-conjugated polyclonal antibodies against cleaved PARP (BD Biosciences 552933) according to manufacturer’s instruction. This was followed
by washing with PBS twice and analysis by Flow cytometer. Percentage of population shifting right in the gate represent population of cells showing
cleavage of caspase substrate PARP. Cleavage of PARP was demonstrated by Western blot analysis using anti PARP antibody (Calbiochem) taking
equal amount of proteins from target cells. Cleavage PARP protein was revealed by presence of two bands, one for full length PARP (119 kD) and
another for cleaved PARP (89 kD) in the Western blot. SMP30 protein (upper panel) was detected by SMP30 antibody and the protein band at ,30
kDa was assessed to determine the efficiency of transfection. a-Tubulin (lower panel) was used as a loading control.
doi:10.1371/journal.pone.0020861.g010
Table 1. Primers used for cloning.
Sequence 59-39
hSMP PCR 1F2 CACCACGCCCGGCTAATTTTG
hSMP PCR 1R1 GGCAACAAAGTGAGACTTCGTCTC
hSMP PCR 2F GGCAGTGCCAACATAGAAGG
hSMP PCR 2R1 CTTCCTCAGTGCTGATGTCTCCC
hSMP30 EcoR I F ACAGAATTCCCTGCGACCATGTCTTCC
hSMP30 Xho I R ACACTCGAGTCCCGCATAGGAGTAGGGA
doi:10.1371/journal.pone.0020861.t001
Table 2. Oligonucleotide used for EMSA.
Sequence 59–39
hSMP30 TRE 1 SS ATGTTGGTCAGGCTGGTCTCAAACTCCTGACCTTAGG
hSMP30 TRE 1 AS CCTAAGGTCAGGAGTTTGAGACCAGCCTGACCAACAT
hSMP30 TRE 2 SS GAAGGACATTAAAGGGACAATTTCTATGACCTGGTG
hSMP30 TRE 2 AS CACCAGGTCATAGAAATTGTCCCTTTAATGTCCTTC
doi:10.1371/journal.pone.0020861.t002
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condition for GAPDH as follows: initial denaturation (94uC
3 min), (94uC4 5 s ,5 6 uC4 5 s ,7 2 uC 45 s) for 30 cycles and
additional extension was performed at 72uC for 5 min. Then PCR
products were electrophoresed in 1.5% agarose gel.
Western Blot Analysis
Whole cell extracts were prepared from cells and Western
blotting was performed as described elsewhere [42]. 100 mgo f
protein from whole cell extract was used for Western analysis. Goat
SMP30 antibody (Santacruz) 1:500 times, cleaved PARP (Calbio-
chem) 1:1000 times, TRb (Abcam) 1:1000 times, SRC-1 (Milipore)
1:2000 times, TRa (Abcam) 1:1000 times, RXRa (Santacruz)
1:1000 times dilution and their respective HRP conjugated
secondary antibody (Santacruz) 1:5000times dilution were used to
detect protein expression in western blot. a- Tubulin antibody
(Santa Cruz) 1:1000times dilution was used for immunodetection
of a- Tubulin protein, which was used as a loading control. West-
ern Blotting Luminol Reagent kit (Amersham) was used for
visualization of bands according to manufacturer’s protocol.
Flow cytometric analysis
To detect intact, necrotic and apoptotic cells, flow cytometry
was performed. MCF-7 cells transfected with mock vector (CMV-
FLAG) and vector containing SMP30 gene as (SMP30-FLAG)
were incubated in presence or absence of 10 mMT 3 for 24 hrs in
culture. Knocking down of endogenous SMP30 expression or non
specific scrambled siRNA was followed by incubation of MCF-7
cells with or without 10 mMT 3. After 24 hrs of incubation cells
were harvested and assayed for apoptosis using the Annexin V
FITC apoptosis detection kit, IMGENEX according to manufac-
turer’s instruction. Cells were analyzed in FACS Calibur Analyzer
(Becton Dickinson) by using Cell Quest Pro software.
Detection of apoptosis by Annexin-V-FITC detection kit was
further confirmed by intracellular staining with PE-conjugated
polyclonal antibody against cleaved PARP (BD Biosciences 552
933) according to manufacturer’s instruction. This was followed by
washing with PBS twice and analysis by Flow cytometer.
Percentage of population shifting right in the gate represent
population of cells showing cleavage of caspase substrate PARP.
Site-directed Mutagenesis
Two bases of the TREs were mutated as shown in the table 6
(bases in bold letter represents mutated base). For mutagenesis of
TREs in hSMP30TRE1 and TRE2 reporter vectors two sets of
PCR were carried out using the following combination of primers:
ForTRE1: hSMP PCR1F2/ hSMP mut TRE1 AS antisense and
hSMP mut TRE1 SS/ hSMP PCR1R1 antisense; for TRE2:
hSMP mut TRE2 sense/ hSMP PCR2R1antisense and hSMP
PCR2F1 sense/hSMP mut TRE2 antisense; The PCR amplifica-
tion for mut TRE1was performed using step cycles (94uC for 30 s,
65uC for 30 s, 74uC 30 s) for 35 cycles with a final extension at
74uC for 10 minutes. The PCR amplification for mut TRE2 was
performed using step cycles (94uC for 30 s, 60uC for 30 s, 72uC
30 s) for 35 cycles with a final extension at 72uC for 10 minutes.
Both the PCR products were purified using QIAquick Gel Ex-
traction Kit. DNA was eluted using 30 ml of autoclaved deionised
water. 30 ng of each PCR product was used as a template for the
second round of PCR. For example: for construction of mutant
TRE1site: 30 ng each of the PCR product hSMP PCR1F2/
hSMP mut TRE1 AS antisense and hSMP mut TRE1 SS/
hSMP PCR1R1 antisense. Similarly mutant TRE2 was made.
PCR amplification was carried out using the same parameters as
mentioned above. Then the PCR products were purified using
QIAquick Gel Extraction Kit. The fragments with mutated TRE
sites, having KpnI and XhoI restriction sites and pGL3-Basic
vector were digested with KpnI and XhoI enzyme. The fragments
were then ligated into restriction enzyme digested pGL3-Basic
vector using DNA ligase. The cloned fragments were then con-
firmed by vector specific PCR using RV3 and GL2 primer, and
the mutation was confirmed by sequencing.
Table 3. Mutated Oligonucleotide used for EMSA.
Sequence 59–39
hSMP30 mutTRE1 SS ATGTTAGTAAGGCTGGTCTCAAACTCCTGAAATTAGG
hSMP30 mutTRE1 AS CCTAATTTCAGGAGTTTGAGACCAGCCTTACTACAT
hSMP30 mutTRE2 SS GAAAGAAATTAAAGGGACAATTCTATGAAATGGTG
hSMP30 mutTRE2 AS CACCATTTCATAGAATTGTCCCTTTAATTTCTTTC
doi:10.1371/journal.pone.0020861.t003
Table 4. Primers used in ChIP PCR.
Sequence 59–39
hSMP PCR 1F1 GGATTCAAGCAATTCTCCTGTCTCAGCC
hSMP XhO2 R ACACTCGAGACAGTCTGGGCTTTCTCC
hSMP PCR 3F1 CTGCAAGACTCACGGTCTAGCAGGTCATTT
hSMP PCR 2R2 CTTCCTCTACTTCCTCAGTGCTGATGTCTC
hSMP non TRE F TGGAGAAAGCCCAGACTGTCAGAT
hSMP non TRE R GGCTGGAAGAATCCTGCAAAG
doi:10.1371/journal.pone.0020861.t004
Table 5. Primers used for RT- PCR.
Sequence 59–39
hSMP30 +560 to +580 GCCACCATTGGAACCAAGTT




Table 6. Primers Used for site directed mutagenesis.
Sequence 59–39
hSMP PCR 1F2 CACCACGCCCGGCTAATTTTG
hSMP30 mutTRE1 SS ATGTTAGTAAGGCTGGTCTCAAACTCCTGAAATTAGG
hSMP30 mutTRE1 AS CCTAATTTCAGGAGTTTGAGACCAGCCTTACTACAT
hSMP PCR 1R1 GGCAACAAAGTGAGACTTCGTCTC
hSMP PCR 2F GGCAGTGCCAACATAGAAGG
hSMP30 mutTRE2 SS GAAAGAAATTAAAGGGACAATTCTATGAAATGGTG
hSMP30 mutTRE2 AS CACCATTTCATAGAATTGTCCCTTTAATTTCTTTC
hSMP PCR 2R1 CTTCCTCAGTGCTGATGTCTCCC
doi:10.1371/journal.pone.0020861.t006
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Figure S1 Determination of hSMP30 Transcription start
site (TSS). Determination of transcription initiation sites by
primer extension analysis. A Lane 1–4, sequencing reactions; lane
5, primer extension product of MCF-7 total RNA, lane 6, labeled
DNA marker from Promega. The sequence corresponding to the
transcription start site has been marked by a line and is
complementary to the sequencing reactions shown in the figure.
B. A schematic diagram of human SMP30 promoter showing two
TREs, CAAT box and transcription start site.
(DOC)
Figure S2 To analyze the effect of T3 on SMP30 Promoter
activity in MCF-7 cell in relation to RXRa. Transient
transfections of hSMP30 TRE1, TRE2 were carried out using
MCF-7 cells. 20 hrs before transfection, cells were plated in
DMEM 10%CS media, at a density of 1610
5 cells per well in 12
well plates. For transient transfection, 0.5 mg of reporter plasmid
DNA, 0.5 mgo fT R b and TRa (TRs), RXRAaexpression vector,
100 ng of pRL-TK control vector and only vector to control cells
were co transfected using Fugene HD transfection reagent (from
Roche) as per manufacture’s instruction. After 24 hrs of trans-
fection, cells were subjected to overnight treatment with 1 mMT 3
and vehicle to control cells in 10% CS –DMEM. Then cell lysates
were prepared and luciferase activities were measured. Values are
the mean of three independent experiments 6 SD normalized to
Renilla activity. *** P,0.0001difference from vehicle control
using ANOVA.
(DOC)
Figure S3 Luciferase activity of SMP30 TREs in HEK293
cell line. Transient transfections of hSMP30 TRE1, TRE2 were
carried out using HEK 293 cells. 20 hrs before transfection, cells
were plated in DMEM 10%CS media, at a density of 1610
5 cells
per well in 12 well plates. For transient transfection, 0.5 mgo f
reporter plasmid DNA, 0.5 mgo fT R b and TRa (TRs), RXRa
expression vector, 100 ng of pRL-TK control vector and only
vector to control cells were co transfected using Fugene HD
transfection reagent (from Roche) as per manufacture’s instruc-
tion. After 24 hrs of transfection, cells were subjected to overnight
treatment with 1 mM T3 and vehicle to control cells in 10% CS –
DMEM. Then cell lysates were prepared and luciferase activities
were measured. Values are the mean of three independent
experiments 6 SD normalized to Renilla activity. ***P,0.0001
difference from vehicle control using ANOVA.
(DOC)
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